The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?
- 30 April 2019
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 106 (2) , 338-349
Abstract
Health disparities exist among minorities in the United States, with differences seen in disease prevalence, mortality, and responses to medications. These differences are multifactorial with genetic variation explaining a portion of this variability. Pharmacogenomics aims to find the effect of genetic variations on drug response, with the goal of optimizing drug therapy and development. Although genome‐wide association studies have been useful in unbiasedly surveying the genome for genetic drivers of clinically relevant phenotypes, most of these studies have been conducted in mainly participants of European and Asian descent, contributing to a growing health disparity in precision medicine. Diversity is important to pharmacogenomic studies, and there may be real advantages to the use of these complex genomes in pharmacogenomics. In this review we will outline some of the advantages and confounders of pharmacogenomics in minorities, describe the role of genetic variation in pharmacologic pathways, and highlight a number of population‐specific findings.Keywords
Funding Information
- National Institute on Minority Health and Health Disparities (R01MD009217)
This publication has 93 references indexed in Scilit:
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association studyThe Lancet, 2013
- Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populationsNature Genetics, 2011
- A new conceptualization of ethnicity for social epidemiologic and health equity researchSocial Science & Medicine, 2010
- A genome-wide association study on African-ancestry populations for asthmaJournal of Allergy and Clinical Immunology, 2010
- Next generation disparities in human genomics: concerns and remediesTrends in Genetics, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Genome-wide association studies in neurological disordersThe Lancet Neurology, 2008
- The Structure of Common Genetic Variation in United States PopulationsThe American Journal of Human Genetics, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003